Elevance Health, Inc. (NYSE:ELV) to Post Q1 2026 Earnings of $13.50 Per Share, Zacks Research Forecasts

Elevance Health, Inc. (NYSE:ELV) – Zacks Research increased their Q1 2026 EPS estimates for shares of Elevance Health in a report released on Wednesday, April 24th. Zacks Research analyst K. Dey now forecasts that the company will post earnings per share of $13.50 for the quarter, up from their previous forecast of $12.58. The consensus estimate for Elevance Health’s current full-year earnings is $37.24 per share.

Several other equities analysts have also recently commented on ELV. UBS Group raised their price target on shares of Elevance Health from $585.00 to $605.00 and gave the company a “buy” rating in a research report on Friday, April 19th. StockNews.com cut shares of Elevance Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 25th. Truist Financial reaffirmed a “buy” rating and set a $600.00 price objective (up from $580.00) on shares of Elevance Health in a research report on Friday, April 19th. Barclays lifted their price objective on shares of Elevance Health from $584.00 to $621.00 and gave the stock an “overweight” rating in a research report on Friday, April 19th. Finally, Wells Fargo & Company lifted their price objective on shares of Elevance Health from $557.00 to $600.00 and gave the stock an “overweight” rating in a research report on Friday, April 19th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $587.42.

Elevance Health Stock Performance

Shares of ELV stock opened at $537.26 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.54. Elevance Health has a 52 week low of $412.00 and a 52 week high of $542.07. The stock has a market capitalization of $124.87 billion, a PE ratio of 20.30, a P/E/G ratio of 1.19 and a beta of 0.78. The firm has a 50 day moving average of $511.89 and a two-hundred day moving average of $486.62.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Thursday, April 18th. The company reported $10.64 EPS for the quarter, beating the consensus estimate of $10.54 by $0.10. Elevance Health had a net margin of 3.64% and a return on equity of 20.62%. The company had revenue of $42.27 billion during the quarter, compared to analysts’ expectations of $42.49 billion. During the same quarter last year, the company posted $9.46 EPS. The firm’s revenue was up .9% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Norges Bank acquired a new position in shares of Elevance Health during the fourth quarter worth about $1,347,434,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Elevance Health during the fourth quarter worth about $467,141,000. Canoe Financial LP increased its stake in shares of Elevance Health by 158.1% during the fourth quarter. Canoe Financial LP now owns 844,122 shares of the company’s stock worth $398,054,000 after acquiring an additional 517,116 shares during the period. Morningstar Investment Services LLC acquired a new position in shares of Elevance Health during the fourth quarter worth about $239,244,000. Finally, Focused Investors Fund L P acquired a new position in shares of Elevance Health during the first quarter worth about $249,884,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Elevance Health

In related news, EVP Felicia F. Norwood sold 14,111 shares of the business’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $533.74, for a total value of $7,531,605.14. Following the completion of the sale, the executive vice president now directly owns 31,460 shares of the company’s stock, valued at $16,791,460.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Elevance Health news, Director Ramiro G. Peru sold 753 shares of Elevance Health stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $500.00, for a total value of $376,500.00. Following the transaction, the director now directly owns 9,109 shares in the company, valued at $4,554,500. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Felicia F. Norwood sold 14,111 shares of Elevance Health stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $533.74, for a total transaction of $7,531,605.14. Following the completion of the transaction, the executive vice president now owns 31,460 shares in the company, valued at $16,791,460.40. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 25th. Investors of record on Monday, June 10th will be given a $1.63 dividend. The ex-dividend date is Monday, June 10th. This represents a $6.52 dividend on an annualized basis and a yield of 1.21%. Elevance Health’s dividend payout ratio (DPR) is presently 24.64%.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.